Edible insects may become essential in the wake of the COVID-19 crisis, but FDA regulation is lacking.
FDA clarifies its generic drug approval process in an effort to encourage market competition.
The most surprising regulatory dimension of the coronavirus crisis may center on the lifting of rules.
The federal government seeks authority over stem cell treatments but risks thwarting medical advancement.
In the face of a massive viral outbreak, a federal regulator issues unprecedented guidance on validating COVID-19 testing.
FDA warns consumers that the agency has not evaluated most CBD products and cannot say they are safe.